CDK

Inhibitory Selectivity
Catalog No.Inhibitor Name CDK1CDK2CDK3CDK4CDK5CDK6CDK7CDK8CDK9CLKCDKCdcOther
A10701Palbociclib HCl
****
***
A10806Roscovitine
*
**
*
ERK2,GST-ERK1,ERK1
A10850SNS-032
*
***
*
*
**
****
GSK-3α,GSK-3β
A11129Dinaciclib
****
****
****
****
A10390Flavopiridol
***
***
***
**
*
A10093AT7519
**
**
**
***
**
*
****
GSK-3β
A11045Flavopiridol HCl
***
***
*
***
***
*
A10494JNJ-7706621
****
****
*
**
Aurora A,Aurora B,VEGFR2
A11105AZD5438
***
****
**
***
A11167MK-8776
**
Chk1,Chk2
A10716PHA-793887
**
****
**
****
****
**
GSK-3β
A10163BS-181 HCl
***
A13811Palbociclib Isethionate
****
***
A11034A-674563
**
Akt1,PKA,GSK-3β
A16386abemaciclib
****
****
A11154BMS-265246
****
****
**
A11164PHA-767491
**
**
*
***
****
****
GSK-3β,MK2,PLK1
A11047Milciclib
*
***
**
*
**
TrkA
A11190R547
****
****
****
GSK-3β
A14136NU6027
*
*
ATR,DNA-PK
A13547P276-00
**
**
**
*
*
***
GSK-3β,PKCα,c-Src
A11220Kenpaullone
*
*
*
GSK-3β,ERK2,c-Src
A15889K03861
****
A14192THZ1
****
A11313AT7519 HCl
**
**
*
**
***
**
*
****
GSK-3β
A15517Purvalanol A
***
*
****
A14437Ro-3306
***
PKCδ,SGK,ERK
A14318SU9516
***
***
**
PDGFR
A13677XL413
****
****
Pim1,CK2
A14273LDC000067
*
*
*
***
A14297ML167
**
A13721TG003
***
A13549Ribociclib
A12216Wogonin
A10471Indirubin
*
GSK-3β
A11347CGP60474
***
***
PKCα
A12352Purvalanol B
****
****
A12438NU 6102
***
****
*
A12989LY2835219 (abemaciclib)
****
***
A14025AMG-925
*
****
FLT3
A15054CVT 313
*
*
*
A15196NVP-LCQ195
****
***
****
CHK2
A15767NU2058
*
*
DNA topoisomerase II ATPase
A15823LY2857785
*
***
***

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.



Items 1 to 50 of 60 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction
Catalog No. Product Name Application Product Information
A12989 SALE

LY2835219 (abemaciclib)

CDK4/6 inhibitor
LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.
A15767

NU2058

CDK inhibitor
NU2058 is a guanine-based CDK inhibitor with IC50 of 17 uM and 26 uM for CDK2 and CDK1.
A15485

AG-024322

CDK inhibitor
AG-24322 is a second generation CDK inhibitor. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models.
A15196

NVP-LCQ195

CDK inhibitor
NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
A15517 SALE

Purvalanol A

CDK inhibitor
Purvalanol A is a potent, cell-permeable cyclin-dependent protein kinase (cdk) inhibitor. IC50 values are 4, 70, 35, 850 and 75 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively.
A15054

CVT-313

CDK2 Inhibitor
CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).
A14025

AMG-925

Dual FLT3/CDK4 inhibitor
AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor.
A14273

LDC000067

CDK inhibitor
LDC000067 is a highly selective CDK9 inhibitor .
A13549 SALE

LEE011 (Ribociclib)

CDK4/6 inhibitor
LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
A13547 SALE

P276-00

CDK Inhibitor
P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. In Phase 2/3
A13677 SALE

BMS-863233 (XL-413)

CDK inhibitor
BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
A14414

CA-224

CDK4 inhibitor
CA-224 is potent CDK4 inhibitor,is also a nonplanar analogue of fascaplysin that specifically inhibits Cdk4-cyclin D1 in vitro.
A13811 SALE

PD 0332991 Isethionate

CDK4/6 inhibitor
PD 0332991 Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM respectively.
A14437 SALE

Ro 3306

CDK1 inhibitor
Ro 3306 is an ATP-competitive, potent cyclin-dependent kinase (cdk) 1 inhibitor (Ki values are 35 and 110 nM for cdk1/cyclin B1 and cdk1/cyclin A respectively).
A13550 SALE

PHA690509

CDK inhibitor
PHA-690509 is a ATP-competitive CDK inhibitor.
A14392

Voruciclib

CDK inhibitor
Voruciclib is a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
A14318 SALE

SU9516

CDK2 inhibitor
SU9516 is a potent, selective cdk2 inhibitor. It inhibits pRb phosphorylation causing enhanced pRB/E2F complex formation and induces G1 and G2-M cell cycle arrest.
A14297

ML167

Clk4 inhibitor
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor
A14136

NU6027

ATR/CDK inhibito
NU6027 is a potent inhibitor of cellular ATR activity (IC(50)=6.7 μM) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner.
A11962 SALE

TG-02 (SB1317)

FLT3 inhibitor
TG-02 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor.
A14192 SALE

THZ1

CDK7 Inhibitor
THZ1 is a novel selective and potent covalent CDK7 inhibitor with IC50(binding affinity) of 3.2 nM; inhibits Jurkat cell's proliferation with IC50 of 50 nM
A13506

AZD5597

CDK inhibitor
AZD5597 is potent CDK inhibitor with in vitro anti-proliferative effects against a range of cancer cell lines.
A13524

NSC 663284

Cdc25 inhibitor
NSC 663284 is a potent, cell-permeable, and irreversible inhibitor of all Cdc25 isoforms, with preference for Cdc25A (IC50 = 29, 95, and 89 nM for Cdc25A, Cdc25B2, and Cdc25C, respectively).
A15039

CDK9 inhibitor 2

CDK9 inhibitor
CDK9-IN-2 is a novel cyclin-dependent kinase 9(CDK9) inhibitor.
A16386

LY2835219 methanesulfonate

CDK4/6 inhibitor
LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
A16325

LY-3177833

CDC7 inhibitor
LY-3177833 is a potent and selective inhibitor of CDC7 (Cell Division Cycle 7-related Protein Kinase).
A15942

Bohemine

CDK inhibitor
Bohemine is a potent and selective, cell-permeable, cyclin-dependent kinase (CDK) inhibitor with IC50 = 1 ,M.
A15889 SALE

K03861

CDK inhibitor
K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.
A14427

Palbociclib

CDK inhibitor
Palbociclib is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
A12584

ON123300

CDK4 inhibitor‎
ON123300 is a potent multikinase inhibitor and may be potential useful for brain tumor chemotherapy. ON123300 strongly inhibits Ark5 and CDK4, as well as growth factor receptor tyrosine kinases such as ??-type platelet-derived growth factor receptor (PDGFR??).
A13130

RGB-286638

CDK inhibitor
RGB-286638 is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 and cyclin D3-CDK6.
A15823 SALE

LY2857785

CDK9 inhibitor
LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.
A12494

NG52

Cell cycle-regulating kinase inhibitor
NG52 is a potent, cell-permeable, reversible, selective, and ATP-compatible inhibitor of the cell cycle-regulating kinase, Cdc28p (IC50 = 7 _mu_M), and the related Pho85p kinase (IC50 = 2 _mu_M).
A15005

AT7519 trifluoroacetate

CDK inhibitor
AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM, less potent to CDK3 and little active to CDK7.
A13721 SALE

TG003

Clk inhibitor
TG003 is a potent, specific, reversible, and ATP competitive inhibitor of Cdc2 like kinase(Clk).-
A12216

Wogonin

CDK9 inhibitor
Wogonin is an anti-inflammatory agent and an inhibitor of CDK9 and does not inhibit CDK2, CDK4 and CDK6 at doses that inhibit CDK9 activity; Also inhibits N-acetyltransferase
A12742

BAY 1000394 (Roniciclib)

CDK inhibitor
BAY 1000394 is an orally bioavailable cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity.
A10494

JNJ-7706621

CDK/Aurora A/B Inhibitor
JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6 in cell-free assays. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.
A11045 SALE

Flavopiridol HCl

CDK inhibitor
Flavopiridol HCl is an inhibitor of cyclin-dependent kinases. The (-)-cis form induces apoptosis in particular tumor cells.
A10163 SALE

BS-181 HCl

CDK inhibitor
BS-181 HCl is a potential anti-tumor agent as CDK7 inhibitor.
A10093 SALE

AT7519

CDK Inhibitor
AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation.
A10716 SALE

PHA-793887

CDK Inhibitor
PHA-793887, a novel potent inhibitor of Cdk, target on kinds of cyclin-dependent kinase under low concentrations and poses high activity against several cancer cell lines.
A10850 SALE

SNS-032 (BMS-387032)

CDK inhibitor
SNS-032 (BMS-387032) is a highly selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9, with in vitro growth inhibitory effects and ability to induce apoptosis in malignant B cells.
A10806 SALE

Roscovitine (Seliciclib)

CDK Inhibitor
Roscovitine (Seliciclib) is a CDK inhibitor that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9.
A11034 SALE

A-674563

Akt inhibitor
A-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
A10471 SALE

Indirubin

CDK & GSK-3β inhibitor
Indirubin, the active constituent of a Chinese antileukaemia medicine, is a potent cyclin-dependent kinases and GSK-3β inhibitor with IC50 of about 5 μM and 0.6 μM.
A10390 SALE

Flavopiridol (Alvocidib)

CDK inhibitor
Flavopiridol (Alvocidib) is a cyclin-dependent kinase inhibitor under clinical development for the treatment of chronic lymphocytic leukemia.
A11047

PHA-848125 (Milciclib)

CDK Inhibitor
PHA-848125 (Milciclib) is an orally bioavailable inhibitor of CDKs and TRKA with potential antineoplastic activity.
A11105

AZD5438

CDK inhibitor
AZD5438 is a potent inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 (IC50 values are 16, 6 and 20 nM respectively).
A12438

NU 6102

CDK inhibitor
NU6102 is selective for CDK1 and CDK2 compared to CDK4/D1 (IC50=1.6 μM), DYRK1A (IC50=0.9 μM), PDK1 (IC50=0.8 μM) and ROCKII (IC50=0.6 μM).

Items 1 to 50 of 60 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction